Authors: Indolfi G, Thorne C, El-Sayed MH, Giaquinto C, Gonzalez-Peralta RP.
Published in: J Pediatr Gastroenterol Nutr. 2017;64(6):851-854
Abstract The development of oral hepatitis C virus (HCV) direct-acting antivirals (DAAs) has revolutionized the therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are commercially available to treat adults with hepatitis C infection. These new regimens for the first time genuinely raise the prospects of eradicating HCV. Many challenges, however, remain from identifying infected individuals to optimizing treatment and ensuring global access to antiviral therapy to all population groups, including children.